DENVER, Aug.  17, 2026  (GLOBE NEWSWIRE) -- Here are today’s catalysts reshaping the market narrative.  NeOnc Technologies Holdings: Phase 2a Data Could Just Be the Beginning  NeOnc (NASDAQ:NTHI) has produced the kind

NTHI

These Nasdaq Stories Are Heating Up

NeOnc Phase 2a data signals CNS delivery platform validity for NEO100

<section class="insight" data-version="1">
 <section data-block="information">
 <h3>Information</h3>
 DENVER, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Here are today’s catalysts reshaping the market narrative. NeOnc Technologies Holdings: Phase 2a Data Could Just Be the Beginning NeOnc (NASDAQ:NTHI) has produced the kind
 </section>

 <section data-block="ai-summary-paragraph">
 <h3>AI Summary</h3>
 NeOnc reported Phase 2a topline results for intranasal NEO100 in recurrent IDH1-mutant high-grade glioma, showing 48.9% six-month progression-free survival and a median OS of 26.09 months. The data may validate nose-to-brain delivery and a broader CNS platform, with a Type B FDA meeting planned and orphan/fast-track designations aiding registrational prospects. If confirmed, NTHI could shift toward lead-product potential and broader partnerships around CNS delivery technologies.
 </section>

 <section data-block="ai-summary-bullets">
 <h3>Key Points</h3>
 <ul><li>Phase 2a NEO100: 48.9% six-month PFS vs 20% benchmark.</li><li>Median OS 26.09 months; 86.7% alive at six months.</li><li>FDA Type B meeting planned for registrational path.</li><li>Orphan Drug, Fast Track, Rare Pediatric Disease designations; UAE IND.</li></ul>
 </section>

 <section data-block="companies-mentioned">
 <h3>Companies Mentioned</h3>
 <ul><li>NeOnc Technologies Holdings (NTHI): Phase 2a NEO100 results; potential lead product and platform validation.</li><li>IP Strategy Holdings (IPST): Microcap with tiny float (~663,500 shares); high liquidity risk.</li><li>OmniAb (OABI): Lilly collaboration; up to $370M milestones; validates discovery platform.</li><li>Eli Lilly &amp; Company (LLY): Partner to OmniAb; pharma validation and potential royalties.</li></ul>
 </section>

 <section data-block="category">
 <h3>Industry News</h3>
 Industry News; the piece highlights multiple biotech catalysts and frames NTHI&#039;s Phase 2a data as a potential inflection point for CNS delivery technology.
 </section>

 <section data-block="market-moving">
 <h3>Market-Moving</h3>
 <ul><li>Positive Phase 2a data could drive near-term NTHI re-rating.</li><li>FDA Type B meeting may define registrational path timeline.</li><li>Small sample size (24) adds durability risk; confirmation needed.</li><li>Orphan/Fast Track designations and UAE IND support regulatory trajectory.</li></ul>
 </section>

 <section data-block="key-facts">
 <h3>Key Facts</h3>
 <ul><li>Aug 12, 2026: topline Phase 2a results for intranasal NEO100.</li><li>48.9% six-month PFS vs 20% historical benchmark.</li><li>Median OS: 26.09 months.</li><li>Six-month survival: 86.7%; 12-month: 60.9%; 24-month: 54.1%.</li><li>Five of 24 patients remained on treatment.</li></ul>
 </section>

 <section data-block="trading-thesis">
 <h3>Trading Thesis</h3>
 Bullish on NTHI near-term; watch for FDA pathway clarity and data readouts over the next 6–12 months.
 </section>
</section>


<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css"></link>DENVER, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Here are today’s catalysts reshaping the market narrative. NeOnc Technologies Holdings: Phase 2a Data Could Just Be the Beginning NeOnc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/NTHI">NTHI</a>) has produced the kind of clinical update that can force investors to reconsider an entire biotech story. On August 12, the company reported topline Phase 2a results for intranasal NEO100 in recurrent IDH1-mutant high-grade glioma, including a 48.9% six-month progression-free survival rate, versus a prespecified 20% historical benchmark. Median overall survival was reported at 26.09 months, with 86.7% of patients alive at six months, 60.9% at 12 months and 54.1% at 24 months. Five of 24 patients remained on treatment. The headline efficacy number is important, but the more intriguing market question may be whether NEO100 is beginning to validate something bigger: NeOnc&#39;s approach to non-invasive nose-to-brain drug delivery. The company&#39;s SEC filings identify NEO100 as an intranasally administered formulation and describe its broader focus as overcoming the blood-brain barrier. NeOnc&#39;s investor materials also describe a pipeline extending beyond NEO100, including NEO212. That platform angle could become increasingly relevant if the company can reproduce the clinical signal in a registrational program and demonstrate that its delivery technology can support additional CNS therapeutics. NeOnc has said it plans to request a Type B FDA meeting regarding a registrational development path, while NEO100 has received FDA Orphan Drug, Fast Track and Rare Pediatric Disease designations. The company also received UAE IND authorization covering its NEO100 programs. Bottom line: NTHI has moved beyond a purely preclinical story. The market now has human Phase 2a efficacy data to evaluate and the next question is whether NEO100 can become the lead product that validates a broader CNS delivery platform. IP Strategy Holdings: Tiny Float, $DATA Treasury and an AI-Data Infrastructure Bet IP Strategy is one of the market&#39;s more unusual microcap stories because the company is effectively combining three narratives: public-market exposure, a digital-asset treasury and infrastructure participation in an emerging AI-data ecosystem. The company describes itself as the first Nasdaq-listed company to adopt $DATA, formerly $IP, as a primary treasury reserve asset while operating validator infrastructure for the DATA Network. Its June validator report showed 200,651.63 $DATA earned from staking during the month and 14,127.47 $DATA in validator fees, with 99.98% uptime. Cumulative staking rewards since September 2025 were reported at approximately 2.47 million $DATA. The extreme share structure adds another layer. Market data recently showed approximately 663,500 shares in the public float, alongside a market capitalization of roughly $1.5 million. That doesn&#39;t make IPST inherently attractive, but it does mean that liquidity and attention can have an unusually large impact on the stock. A microfloat can magnify upside moves—and downside moves. The strategic thesis ultimately rests on whether the DATA ecosystem becomes commercially meaningful. IP Strategy is betting that trusted, attributable and verifiable data becomes increasingly important as AI developers grapple with data provenance, rights and monetization. The company has also emphasized the transition from Story Foundation to The DATA Foundation and the launch of the DATA Network. Bottom line: IPST is a high-risk convergence play on AI, digital assets and blockchain infrastructure. Its tiny float makes the stock particularly speculative, but the company&#39;s validator operations and $DATA treasury give the story a business angle beyond simply owning cryptocurrency. OmniAb: Lilly Just Put A $370 Million Number on the Table OmniAb is getting a potentially significant vote of confidence from one of the world&#39;s largest pharmaceutical companies. OmniAb announced a global collaboration and license agreement with Eli Lilly &amp; Company for a new ion-channel program, with OmniAb eligible for up to $370 million in research, development and commercial milestones, plus tiered royalties on global net sales. The target and therapeutic modality are undisclosed, but the strategic fit is notable. OmniAb has developed specialized capabilities around difficult therapeutic targets, including ion channels, alongside its antibody-discovery platform. The company says its ecosystem includes more than 100 biopharmaceutical companies and research institutions, while its technology combines transgenic animal platforms with high-throughput screening and AI-enabled discovery tools. The Lilly agreement also arrives after OmniAb reported a strong first quarter in which revenue reached $14.4 million, compared with $4.2 million a year earlier, largely reflecting milestone revenue. Earlier company disclosures showed 107 active partners and 409 active programs, with 98% of those programs carrying contracted future economics and more than $3 billion in contracted milestones. That is the attraction of the OmniAb model. Investors aren&#39;t necessarily betting on one internally developed blockbuster. They are betting that OmniAb&#39;s discovery technologies can repeatedly be inserted into pharmaceutical development programs—and that some of those programs ultimately generate milestones and royalties. The risk is equally clear: milestones are contingent, programs can fail and royalty economics depend on successful commercialization. Bottom line: The Lilly deal potentially reinforces the idea that OABI is becoming a biotech picks-and-shovels platform rather than a conventional single-asset biotech. The $370 million headline is contingent, but the pharmaceutical validation is real. About 24/7 Market News In today&#39;s fast-moving markets, visibility is everything and 24/7 Market News (24/7) provides a powerful suite of investor relations and public relations solutions designed to elevate your company’s profile quickly and effectively. Whether you&#39;re an established name seeking broader awareness, or a micro-cap looking to break out of obscurity, 24/7 delivers targeted, high-impact coverage through timely news distribution, analyst report placements, featured editorials, and multi-channel amplification across financial platforms, social media, and investor communities. Our services help cut through the noise, attract institutional interest, drive exposure, and build long-term shareholder credibility, all while maintaining full SEC compliance and transparency. For Analyst Report coverage, custom IR campaigns, press release syndication, or other tailored investor and public relations solutions, contact <a href="https://www.globenewswire.com/Tracker?data=Zu6lzFCMbi2dAoz6_DKUXyiZd3rYAFbqIfcy9U-kHZaMiew6aEjaDoME_4tGdZpfUM7AnKjsBmwPhFkErHxNqOkwrXMT3rAoBrb4-F0DH_s=" rel="nofollow" target="_blank">sales@247mnn.com</a> to discuss how 24/7 can help accelerate your company’s visibility and valuation trajectory. This is a paid editorial communication intended for informational purposes only. 24/7 is compensated by NTHI to provide ongoing news coverage of expected upcoming catalysts and events as well as market outreach services. This should not be construed as financial or investment advice. Trading involves substantial risk; consult your financial advisor. For further information, please visit 247mnn.com. Important Editorial Note: 247 highlights companies approaching significant catalysts and inflection points. This report reflects information available at the time of publication. Since developments can occur rapidly, readers should independently verify current information and review all company filings and disclosures. CONTACT: 24/7 Market News <a href="https://www.globenewswire.com/Tracker?data=4mZiAo-9Zr911tPNXqPCrbMKYiJW554_GrSShK6F76Vl_W3CN8MRZKWjR7l-iWsgffMTNtEG_pvzX02RyRkFn904ZgaV4f2s_GvpifWGaZs=" rel="nofollow" target="_blank">Editor@247mnn.com</a> Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the Company&#39;s ability to grow its business and other statements that are not historical facts, including statements which may be accompanied by the words &#34;intends,&#34; &#34;may,&#34; &#34;will,&#34; &#34;plans,&#34; &#34;expects,&#34; &#34;anticipates,&#34; &#34;projects,&#34; &#34;predicts,&#34; &#34;estimates,&#34; &#34;aims,&#34; &#34;believes,&#34; &#34;hopes,&#34; &#34;potential&#34; or similar words. Actual results could differ materially from those described in these forward-looking statements due to a number of factors, including without limitation, the Company&#39;s ability to continue as a going concern, general economic conditions, and other risk factors detailed in the Company&#39;s filings with the SEC. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake any responsibility to update such forward-looking statements except in accordance with applicable law. <img alt="" class="__GNW8366DE3E__IMG" src="https://www.globenewswire.com/newsroom/ti?nf=OTgxMTUyMCM3NzgwNDY1IzIzMDQzNjM="></img> <img alt="" src="https://ml.globenewswire.com/media/ZmM4NTUyZWItNGU5NS00NzQyLTlmODUtODNhMTljMmEwNDBkLTEzMTU5MTMtMjAyNi0wOC0xNy1lbg==/tiny/24-7-Market-News.png" referrerpolicy="no-referrer-when-downgrade"></img>

NeOnc reported Phase 2a topline results for intranasal NEO100 in recurrent IDH1-mutant high-grade glioma, showing 48.9% six-month progression-free survival and a median OS of 26.09 months. The data may validate nose-to-brain delivery and a broader CNS platform, with a Type B FDA meeting planned and orphan/fast-track designations aiding registrational prospects. If confirmed, NTHI could shift toward lead-product potential and broader partnerships around CNS delivery technologies.

News insight

These Nasdaq Stories Are Heating Up

AI summary

Sentiment rationale

Key facts

Industry News